Abstract

Background and ImportanceBreast cancer is the world’s most prevalent cancer. There are approximately 55000 new diagnosed cases per year in Italy. CDK4/6 inhibitors are targeted orally available cancer drugs. These...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future
T Robinson ... J.P Braybrooke
Clinical oncology (Royal College of Radiologists (Great Britain)) | VOL. 32
T Robinson, et. al.T Robinson ... J.P Braybrooke
14 May 2020
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Robert J Cersosimo
American Journal of Health-System Pharmacy | VOL. 76
Robert J CersosimoRobert J Cersosimo
01 Aug 2019
PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come
Leticia De Mattos-Arruda
ESMO open | VOL. 5
Leticia De Mattos-ArrudaLeticia De Mattos-Arruda
01 Jan 2020
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.
Ram Patel ... Abdullah Nasser
Journal of Clinical Oncology | VOL. 42
Ram Patel, et. al.Ram Patel ... Abdullah Nasser
01 Jun 2024
View more papers

More From: European Journal of Hospital Pharmacy: Science and Practice

Paper Title
Journal
Date
Author
Patient reported medication-related problems, adherence and waste of oral anticancer medication over time
Patricia M L A Van Den Bemt ... Liset Van Dijk
European Journal of Hospital Pharmacy: Science and Practice | VOL. -
Patricia M L A Van Den Bemt, et. al.Patricia M L A Van Den Bemt ... Liset Van Dijk
17 Jul 2024
Pharmacotherapy of carbamazepine-treated patient after bariatric surgery: a complex interplay between altered absorption and drug–drug interactions
Alena Pilková ... Martin Matoulek
European Journal of Hospital Pharmacy: Science and Practice | VOL. -
Alena Pilková, et. al.Alena Pilková ... Martin Matoulek
17 Jul 2024
Risk assessment of clinical trial protocols: a tool for hospital pharmacists to reduce human error in experimental drug management
Giulia Cancellieri ... Piera Polidori
European Journal of Hospital Pharmacy: Science and Practice | VOL. -
Giulia Cancellieri, et. al.Giulia Cancellieri ... Piera Polidori
15 Jul 2024
How can oral second-line anti-tuberculosis medications be administered to an extremely preterm neonate?
Tien Thuy Ngo ... Charis Lau
European Journal of Hospital Pharmacy: Science and Practice | VOL. -
Tien Thuy Ngo, et. al.Tien Thuy Ngo ... Charis Lau
13 Jul 2024
View more papers